Member Type: Diagnostic Companies
Metamark is a privately held company dedicated to improving cancer care by providing the next generation of diagnostic and prognostic testing. The company is advancing its contribution to oncology through its proprietary genomics and proteomics discovery platforms, a growing clinical research effort and corporate alliances. Metamark has assembled a unique portfolio of testing services and products to inform critical decisions at each step of the care pathway in prostate cancer. The company’s interests also include bladder, colon and breast cancers.